Prior to the approval of<unk> , two studies were conducted to evaluate the safety of the formulation. Adverse reactions for at least 5% of people taking it were hypoglycemia, nausea, nasopharyngitis, diarrhea, upper respiratory tract infections, and headache. In Study A (N=469), symptoms of hypoglycemia were recorded in 25.6% of people with zero cases of severe symptomatic hypoglycemia. Study B (N=365) had a 40% incidence of hypoglycemic events with 1.1% incidence of severe hypoglycemia requiring assistance.
Insulin glargine/lixisenatide
Insulin degludec/liraglutide
Insulin degludec/insulin aspart
Insulin glulisine
NPH insulin
Glibenclamide/metformin
Insulin detemir
Lente insulin